The emergence of liquid biopsy is bringing targeted therapies and molecular diagnostic tests together in a highly synergistic way. Liquid biopsies offer potentially transformative improvements in cancer care due to their ability to rapidly interrogate the molecular basis of disease in a way that classic tissue biopsies cannot.

To understand the current usage and future potential of liquid biopsy, we brought together experts from a range of disciplines to answer the following question: What is the current and future clinical utility of liquid biopsy based testing in oncology?

This report presents the findings of these discussions and considers how to address the technical bottlenecks to broad clinical adoption of liquid biopsy.

Request the whitepaper

Author
James Blakemore
Senior Consultant

James is a Senior Market Strategy Consultant within our Medical Technology Consulting Group.